Aptinyx (NASDAQ:APTX – Get Rating) posted its quarterly earnings results on Thursday. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.02, Fidelity Earnings reports. During the same quarter in the prior year, the business posted ($0.22) earnings per share.
APTX stock opened at $0.70 on Friday. Aptinyx has a one year low of $0.57 and a one year high of $4.73. The stock has a market cap of $47.40 million, a PE ratio of -0.59 and a beta of 1.46. The firm has a 50 day simple moving average of $1.78 and a two-hundred day simple moving average of $2.43. The company has a debt-to-equity ratio of 0.15, a current ratio of 20.18 and a quick ratio of 20.18.
A number of analysts recently weighed in on APTX shares. HC Wainwright decreased their target price on shares of Aptinyx from $8.00 to $2.00 and set a “buy” rating on the stock in a report on Thursday, April 14th. William Blair lowered shares of Aptinyx from an “outperform” rating to a “market perform” rating in a report on Thursday, April 7th. Truist Financial decreased their target price on shares of Aptinyx from $12.00 to $5.00 and set a “buy” rating on the stock in a report on Friday, April 8th. BMO Capital Markets decreased their target price on shares of Aptinyx from $12.00 to $6.00 in a report on Friday, April 8th. Finally, SVB Leerink decreased their target price on shares of Aptinyx from $10.00 to $4.00 and set an “outperform” rating on the stock in a report on Thursday, April 21st. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $3.88.
Aptinyx Company Profile (Get Rating)
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia.
- Get a free copy of the StockNews.com research report on Aptinyx (APTX)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Want More Great Investing Ideas?
- 3 Stocks to DOUBLE This Year
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 9 "MUST OWN" Growth Stocks
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.